Gangliosidosis
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Gangliosidosis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Gangliosidosis Local Doctors?
Elite in Gangliosidosis
Medical Genetics
Elite in Gangliosidosis
Medical Genetics
111 Michigan Ave Nw, 
Washington, DC 
Languages Spoken:
English

Cynthia Tifft is a Medical Genetics provider in Washington, Washington, D.c.. Dr. Tifft is rated as an Elite provider by MediFind in the treatment of Gangliosidosis. Her top areas of expertise are Sandhoff Disease, Gangliosidosis, GM1 Gangliosidosis, and Tay-Sachs Disease.

Elite in Gangliosidosis
Elite in Gangliosidosis
Kingston, ON, CA 

Jagdeep Walia practices in Kingston, Canada. Mr. Walia is rated as an Elite expert by MediFind in the treatment of Gangliosidosis. His top areas of expertise are Sandhoff Disease, Tay-Sachs Disease, Gangliosidosis, and Medium-Chain Acyl-CoA Dehydrogenase Deficiency.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Gangliosidosis
Pediatric Neurology
Elite in Gangliosidosis
Pediatric Neurology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
Languages Spoken:
English

Florian Eichler is a Pediatric Neurologist in Boston, Massachusetts. Dr. Eichler is rated as an Elite provider by MediFind in the treatment of Gangliosidosis. His top areas of expertise are Adrenoleukodystrophy (ALD), CACH Syndrome, Tay-Sachs Disease, Gangliosidosis, and Gastrostomy.

What are the latest Gangliosidosis Clinical Trials?
Longitudinal Study of Neurodegenerative Disorders

Summary: The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.

Match to trials
Find the right clinical trials for you in under a minute
Get started
18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Summary: An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis